Arthur Stril
CFO & Chief Business Officer at Cellectis
Second, thanks to the progress of our collaboration with AstraZeneca, up to year end 2024, dollars '40 '7 million have been paid to select this under the joint research and collaboration agreement, of which $25,000,000 upfront and $22,000,000 reached development milestones in addition to reimbursement of research costs incurred. Third, last year, we drew down the second tranche of EUR 15,000,000 and the third and final tranche of EUR 5,000,000 under the credit facility agreement entered with the European Investment Bank, EIB, in 2022. Following such activities are cash, cash equivalents, restricted cash and fixed term deposits classified as current financial assets as of 12/31/2024, amount to $264,000,000 compared to $156,000,000 as of 12/31/2023. This $108,000,000 increase is mainly due to $140,000,000 cash received from AstraZeneca as part of the second tranche of its equity investment in Selectus, dollars twenty million cash received from the EIB pursuant to the disbursement of the second and third tranches under the finance contract with EIB, forty three million dollars of cash in from our revenue, partially offset by cash payments from Selective to suppliers of $47,000,000 Selective wages, bonuses and social expenses paid of $40,000,000 the payments of lease debts of $11,000,000 and the repayment of the PGE loan of $5,000,000 You are invited to refer to our press release for figures related to consolidated net loss attributable to shareholders of Selective for the twelve months ended 12/31/2024.
